Literature DB >> 33811139

Active p38α causes macrovesicular fatty liver in mice.

Ilona Darlyuk-Saadon1,2, Chen Bai1,2, Chew Kiat Matthew Heng1,3, Nechama Gilad1,4, Wei-Ping Yu5,6, Pei Yen Lim7, Amaury Cazenave-Gassiot7, Yongliang Zhang2,8, W S Fred Wong1,3,8, David Engelberg9,2,4.   

Abstract

One third of the western population suffers from nonalcoholic fatty liver disease (NAFLD), which may ultimately develop into hepatocellular carcinoma (HCC). The molecular event(s) that triggers the disease are not clear. Current understanding, known as the multiple hits model, suggests that NAFLD is a result of diverse events at several tissues (e.g., liver, adipose tissues, and intestine) combined with changes in metabolism and microbiome. In contrast to this prevailing concept, we report that fatty liver could be triggered by a single mutated protein expressed only in the liver. We established a transgenic system that allows temporally controlled activation of the MAP kinase p38α in a tissue-specific manner by induced expression of intrinsically active p38α allele. Here we checked the effect of exclusive activation in the liver. Unexpectedly, induction of p38α alone was sufficient to cause macrovesicular fatty liver. Animals did not become overweight, showing that fatty liver can be imposed solely by a genetic modification in liver per se and can be separated from obesity. Active p38α-induced fatty liver is associated with up-regulation of MUC13, CIDEA, PPARγ, ATF3, and c-jun mRNAs, which are up-regulated in human HCC. Shutting off expression of the p38α mutant resulted in reversal of symptoms. The findings suggest that p38α plays a direct causative role in fatty liver diseases and perhaps in other chronic inflammatory diseases. As p38α activity was induced by point mutations, it could be considered a proto-inflammatory gene (proto-inflammagene).

Entities:  

Keywords:  active variants; fatty liver; lipidosis; p38; transgenic mice

Year:  2021        PMID: 33811139      PMCID: PMC8040811          DOI: 10.1073/pnas.2018069118

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  79 in total

1.  Cidea promotes hepatic steatosis by sensing dietary fatty acids.

Authors:  Linkang Zhou; Li Xu; Jing Ye; De Li; Wenshan Wang; Xuanhe Li; Lizhen Wu; Hui Wang; Feifei Guan; Peng Li
Journal:  Hepatology       Date:  2012-06-01       Impact factor: 17.425

2.  Hepatocyte-specific, PPARγ-regulated mechanisms to promote steatosis in adult mice.

Authors:  Abigail Wolf Greenstein; Neena Majumdar; Peng Yang; Papasani V Subbaiah; Rhonda D Kineman; Jose Cordoba-Chacon
Journal:  J Endocrinol       Date:  2016-10-31       Impact factor: 4.286

Review 3.  Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.

Authors:  Zobair Younossi; Frank Tacke; Marco Arrese; Barjesh Chander Sharma; Ibrahim Mostafa; Elisabetta Bugianesi; Vincent Wai-Sun Wong; Yusuf Yilmaz; Jacob George; Jiangao Fan; Miriam B Vos
Journal:  Hepatology       Date:  2019-06       Impact factor: 17.425

4.  Isolation of intrinsically active (MEK-independent) variants of the ERK family of mitogen-activated protein (MAP) kinases.

Authors:  Vered Levin-Salomon; Konstantin Kogan; Natalie G Ahn; Oded Livnah; David Engelberg
Journal:  J Biol Chem       Date:  2008-10-01       Impact factor: 5.157

Review 5.  Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease.

Authors:  Peter J Barnes
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

6.  Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine.

Authors:  J Raingeaud; S Gupta; J S Rogers; M Dickens; J Han; R J Ulevitch; R J Davis
Journal:  J Biol Chem       Date:  1995-03-31       Impact factor: 5.157

Review 7.  The role of PNPLA3 in health and disease.

Authors:  Piero Pingitore; Stefano Romeo
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2018-06-20       Impact factor: 4.698

8.  Hepatic mitogen-activated protein kinase phosphatase 1 selectively regulates glucose metabolism and energy homeostasis.

Authors:  Ahmed Lawan; Lei Zhang; Florian Gatzke; Kisuk Min; Michael J Jurczak; Mashael Al-Mutairi; Patric Richter; Joao Paulo G Camporez; Anthony Couvillon; Dominik Pesta; Rachel J Roth Flach; Gerald I Shulman; Anton M Bennett
Journal:  Mol Cell Biol       Date:  2014-10-13       Impact factor: 4.272

9.  Dual-Specificity Phosphatase 26 Protects Against Nonalcoholic Fatty Liver Disease in Mice Through Transforming Growth Factor Beta-Activated Kinase 1 Suppression.

Authors:  Ping Ye; Jijun Liu; Wuping Xu; Denghai Liu; Xiangchao Ding; Sheng Le; Hao Zhang; Shanshan Chen; Manhua Chen; Jiahong Xia
Journal:  Hepatology       Date:  2019-05       Impact factor: 17.425

10.  Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans.

Authors:  Jan Borén; Martin Adiels; Elias Björnson; Niina Matikainen; Sanni Söderlund; Joel Rämö; Marcus Ståhlman; Pietari Ripatti; Samuli Ripatti; Aarno Palotie; Rosellina M Mancina; Antti Hakkarainen; Stefano Romeo; Chris J Packard; Marja-Riitta Taskinen
Journal:  JCI Insight       Date:  2020-12-17
View more
  1 in total

1.  Autophagy impairment in liver CD11c+ cells promotes non-alcoholic fatty liver disease through production of IL-23.

Authors:  Lauriane Galle-Treger; Doumet Georges Helou; Christine Quach; Emily Howard; Benjamin P Hurrell; German R Aleman Muench; Pedram Shafiei-Jahani; Jacob D Painter; Andrea Iorga; Lily Dara; Juliet Emamaullee; Lucy Golden-Mason; Hugo R Rosen; Pejman Soroosh; Omid Akbari
Journal:  Nat Commun       Date:  2022-03-17       Impact factor: 17.694

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.